Cooperative Oncology Group / Qiagen / Oncolytics Biotech Inc. / Bone Sarcoma Group / Clinical Trials Group / Ventana Medical Systems / Churchill Hospital NHS Trust / Cox / Targeted Therapy Laboratory / Chester Beatty Laboratories / /
Country
United Kingdom / United States / / /
Event
FDA Phase / /
Facility
National Cancer Institute of Canada / Ohio State University Medical Center / Thomas's Hospital / Leeds Institute of Molecular Medicine Group / Churchill Hospital / University of Surrey / Lung Research Institute / Cambridge Research Institute / Mayo Clinic / / /
IndustryTerm
treatment of ovarian cancer / Cancer Therapy / Treatment of Cancer / therapy for cancer / therapy for prostate cancer / unknown primary site / treatment of gastric cancer / /
MedicalCondition
ovarian cancer / metastatic prostate cancer / solid tumours / JE / HIV / dementia / significant synergistic tumor / objective disease / posttreatment tumor / hepatitis B / melanoma / non-small cell lung cancer / lymphopenia / diarrhea / esophageal cancer / remote tumor / prostate cancer / hormone-refractory prostate cancer / breast cancer / Brain tumor / greater neutropenia / reovirus-resistant tumor / tumor / colon carcinoma / Cancer / tumors / brain metastases / liver metastasis / subcutaneous tumors / hepatocellular carcinoma / chills / advanced solid tumors / human cancer / neutropenia / fever / viremia / vomiting / p53 mutant tumor / metastatic mesothelioma / stable disease / gastroesophageal carcinoma / herpes simplex virus / metastases / local inflammatory response / distant metastases / enhanced tumor / gastric carcinoma / gastric cancer / Advanced Cancer Charles Comins1 / headache / metastasis / ocular melanoma / metastatic solid tumors / solid tumors / nausea / herpes / carcinoma / J Cancer / murine lymphoma / ribonucleotide reductase-negative herpes simplex virus / mesothelioma / fatigue / objective radiological tumor / Toxicity Neutropenia Neutropenia / accessible metastases / metastatic breast carcinoma / Spickard A. Reovirus infections / clinically significant cardiac disease / solid cancers / head and neck cancer / evaluable disease / lung metastases / sepsis / radiologically stable disease / cancers / anthracycline-resistant breast cancer / liver metastases / disease / murine malignant melanoma / reovirus-infected tumor / high disease / unknown primary tumor / C infections / advanced cancer / pancreatic carcinoma / advanced / refractory cancer / pain / late tumor / recurrent malignant gliomas / carcinomas / Mol Cancer / diffuse liver metastases / prostate carcinoma / target lymph node metastases / /
Ohio State University Medical Center / American Association for Cancer Research Published OnlineFirst / University of Surrey / New York Heart Association / American Association for Cancer Research / NHS / Churchill Hospital / European Organization for Research and Treatment of Cancer / Heart and Lung Research Institute / Leeds Institute of Molecular Medicine Group / Guys and St. Thomas's Hospital / Intravenous administration / Postgraduate Medical School / National Cancer Institute of Canada / Guys and St. Thomas' NHS Trust / AACR Publications Department / /
Person
Andrew Protheroe / Chris Lyne / Ann Oncol / Arch Virol / Cohort / Kathleen Sergott / James Spicer / / /
Published OnlineFirst October 6, 2010; DOI:[removed].CCR[removed]REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer Charles Comins, James Spicer, Andrew Protheroe, et